Press "Enter" to skip to content

Pfizer Oral Treatment for Home use Approved

The US approved Pfizer Inc’s COVID-19 antiviral pill for persons aged 12 and above who are at risk of severe disease on Wednesday, making it the first oral and at-home treatment as well as a new tool against the fast-spreading Omicron strain.

According to results from Pfizer clinical trial, Paxlovid, an antiviral regimen, was nearly 90% effective in reducing hospitalizations and deaths in individuals at high risk of severe illness. According to, recent lab data indicates that the medication is still effective against Omicron.

Pfizer increased its manufacturing predictions for 2022 to 120 million treatment courses, up from 80 million, and said it was ready to begin delivery in the United States immediately. A new medicine plus an older antiviral called ritonavir make up the treatment’s two-drug regimen. According to White House COVID-19 response coordinator Jeff Zients, the US government will have 265,000 treatment courses accessible by January, with supply ramping up in the months after that. Within six months, the government expects to receive the 10 million courses it has requested. This year, Pfizer claims to have 180,000 treatment courses ready to ship.

The government of the United States has placed a contract for 10 million courses of the medicine at a cost of $530 each course. The FDA’s decision to provide emergency approval for the treatment comes as the United States battles an outbreak of COVID-19 cases caused by the Omicron form, with President Joe Biden announcing plans for new federal immunisation and testing locations. Monoclonal antibodies are usually administered intravenously in hospitals, are not generally available, and cost more than twice as much as a Pfizer pill.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *